Sinus bradycardia after intravenous pulse methylprednisolone therapy in patients with systemic lupus erythematosus

Mod Rheumatol. 2019 Jul;29(4):700-703. doi: 10.1080/14397595.2016.1276246. Epub 2017 Feb 1.

Abstract

Sinus bradycardia is reported as an adverse effect of high-dose glucocorticoid therapy. We report three cases of systemic lupus erythematosus, wherein intravenous pulse methylprednisolone was administered. The patients' average baseline heart rate was 72 beats/min, which decreased 30% from baseline at 61 h after beginning the therapy. The average minimum heart rate was 38 beats/min, and this rate continued for 169 h on average. No other causes for bradycardia were found, suggesting that the administration of glucocorticoid pulse therapy resulted in decreased heart rate.

Keywords: SLE; Sinus bradycardia; glucocorticoid pulse therapy.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Bradycardia / etiology*
  • Cardiotoxicity
  • Female
  • Glucocorticoids / adverse effects*
  • Glucocorticoids / therapeutic use
  • Humans
  • Lupus Erythematosus, Systemic / drug therapy*
  • Methylprednisolone / adverse effects*
  • Methylprednisolone / therapeutic use
  • Middle Aged
  • Sick Sinus Syndrome / etiology*

Substances

  • Glucocorticoids
  • Methylprednisolone